[go: up one dir, main page]

WO2004011489A3 - Tropism-modified adenoviral vectors, preferably for targeting b-lymphocytes or ovarian cells - Google Patents

Tropism-modified adenoviral vectors, preferably for targeting b-lymphocytes or ovarian cells Download PDF

Info

Publication number
WO2004011489A3
WO2004011489A3 PCT/FR2003/002315 FR0302315W WO2004011489A3 WO 2004011489 A3 WO2004011489 A3 WO 2004011489A3 FR 0302315 W FR0302315 W FR 0302315W WO 2004011489 A3 WO2004011489 A3 WO 2004011489A3
Authority
WO
WIPO (PCT)
Prior art keywords
lymphocytes
adenovirus
fiber
tropism
cells
Prior art date
Application number
PCT/FR2003/002315
Other languages
French (fr)
Other versions
WO2004011489A2 (en
Inventor
Halluin Jean Claude D
Laurence Renaut
Morvane Colin
Original Assignee
Inst Nat Sante Rech Med
Halluin Jean Claude D
Laurence Renaut
Morvane Colin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Halluin Jean Claude D, Laurence Renaut, Morvane Colin filed Critical Inst Nat Sante Rech Med
Priority to AU2003273463A priority Critical patent/AU2003273463A1/en
Publication of WO2004011489A2 publication Critical patent/WO2004011489A2/en
Publication of WO2004011489A3 publication Critical patent/WO2004011489A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention concerns recombinant adenoviruses whereof the tropism has been modified to enable B-lymphocytes or ovarian cells to be infected thereby. The inventive recombinant adenoviruses exhibit a reduced tropism compared to that of the native adenovirus. The invention also concerns methods for preparing said adenoviruses, as well as their uses, in particular for transferring DNA sequences into B-lymphocytes or ovarian cells in vitro, ex vivo or in vivo, for experimental, industrial, vaccination or therapeutic purposes. The invention more specifically concerns the modification of the gene of the adenovirus fiber for targeting B-lymphocytes or ovarian cells, in particular tumor cells, as well as other modifications and/or constructs enabling the viruses to be provided with a character specific to said cells. The invention is particularly characterized either by insertion into the fiber of the sequence of a peptide identifying a receptor expressed at the surface of B-lymphocytes, or by replacing the Mastadenovirus adenovirus fiber bud with a fiber bud of a phylogenetically distant adenovirus, preferably of the bovine adenovirus serotype 4 (BAV4).
PCT/FR2003/002315 2002-07-25 2003-07-22 Tropism-modified adenoviral vectors, preferably for targeting b-lymphocytes or ovarian cells WO2004011489A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003273463A AU2003273463A1 (en) 2002-07-25 2003-07-22 Tropism-modified adenoviral vectors, preferably for targeting b-lymphocytes or ovarian cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0209426A FR2842823A1 (en) 2002-07-25 2002-07-25 MODIFIED ADENOVIRUSES FOR TARGETING B-LYMPHOCYTES
FR02/09426 2002-07-25

Publications (2)

Publication Number Publication Date
WO2004011489A2 WO2004011489A2 (en) 2004-02-05
WO2004011489A3 true WO2004011489A3 (en) 2004-07-01

Family

ID=30011465

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/002315 WO2004011489A2 (en) 2002-07-25 2003-07-22 Tropism-modified adenoviral vectors, preferably for targeting b-lymphocytes or ovarian cells

Country Status (3)

Country Link
AU (1) AU2003273463A1 (en)
FR (1) FR2842823A1 (en)
WO (1) WO2004011489A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0709209A2 (en) * 2006-03-28 2011-06-28 Procter & Gamble hydride reduction process for preparation of quinolone intermediates

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006826A1 (en) * 1995-08-14 1997-02-27 Commonwealth Scientific And Industrial Research Organisation Gene therapy using ovine adenoviral vectors
WO1998040508A1 (en) * 1997-03-14 1998-09-17 Selective Genetics, Inc. Adenoviral vectors with modified tropism
WO1998054346A1 (en) * 1997-05-28 1998-12-03 Genvec, Inc. Alternatively targeted adenovirus
WO1999047180A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Chimeric adenoviral vectors for targeted gene delivery
WO2000073478A2 (en) * 1999-06-01 2000-12-07 University Of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
WO2001092547A2 (en) * 2000-05-31 2001-12-06 University Of Saskatchewan Modified bovine adenovirus having altered tropism

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006826A1 (en) * 1995-08-14 1997-02-27 Commonwealth Scientific And Industrial Research Organisation Gene therapy using ovine adenoviral vectors
WO1998040508A1 (en) * 1997-03-14 1998-09-17 Selective Genetics, Inc. Adenoviral vectors with modified tropism
WO1998054346A1 (en) * 1997-05-28 1998-12-03 Genvec, Inc. Alternatively targeted adenovirus
WO1999047180A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Chimeric adenoviral vectors for targeted gene delivery
WO2000073478A2 (en) * 1999-06-01 2000-12-07 University Of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
WO2001092547A2 (en) * 2000-05-31 2001-12-06 University Of Saskatchewan Modified bovine adenovirus having altered tropism

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
CURIEL D T: "STRATEGIES TO ADAPT ADENOVIRAL VECTORS FOR TARGETED DELIVERY", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK ACADEMY OF SCIENCES, NEW YORK, NY, US, vol. 886, 1999, pages 158 - 171, XP000979449, ISSN: 0077-8923 *
DAN ADAM ET AL: "Analysis of the hexon gene sequence of bovine adenovirus type 4 provides further support for a new adenovirus genus (Atadenovirus)", JOURNAL OF GENERAL VIROLOGY, vol. 79, no. 6, June 1998 (1998-06-01), pages 1453 - 1460, XP002276148, ISSN: 0022-1317 *
DATABASE GENBANK [online] NCBI; 16 April 2001 (2001-04-16), DAN A ET AL.: "Bovine Adenovirus 4", XP002276150, Database accession no. AF036092 *
HESS MICHAEL ET AL: "The complete nucleotide sequence of the egg drop syndrome virus: An intermediate between mastadenoviruses and aviadenoviruses", VIROLOGY, vol. 238, no. 1, 10 November 1997 (1997-11-10), pages 145 - 156, XP004460036, ISSN: 0042-6822 *
ISRAEL BRUCE F ET AL: "Enhancement of adenovirus vector entry into CD70-positive B-cell lines by using a bispecific CD70-adenovirus fiber antibody", JOURNAL OF VIROLOGY, vol. 75, no. 11, June 2001 (2001-06-01), pages 5215 - 5221, XP002265173, ISSN: 0022-538X *
KIRBY I ET AL: "MUTATIONS IN THE DG LOOP OF ADENOVIRUS TYPE 5 FIBER KNOB PROTEIN ABOLISH HIGH-AFFINITY BINDING TO ITS CELLULAR RECEPTOR CAR", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 73, no. 11, November 1999 (1999-11-01), pages 9508 - 9514, XP000984778, ISSN: 0022-538X *
KRASNYKH VICTOR ET AL: "Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 75, no. 9, May 2001 (2001-05-01), pages 4176 - 4183, XP002202288, ISSN: 0022-538X *
SEGERMAN A ET AL: "Adenovirus types 11p and 35p show high binding efficiencies for committed hematopoietic cell lines and are infective to these cell lines", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 3, February 2000 (2000-02-01), pages 1457 - 1467, XP002161682, ISSN: 0022-538X *
SEGGERN VON D J ET AL: "ADENOVIRUS VECTOR PSEUDOTYPING IN FIBER-EXPRESSING CELL LINES: IMPROVED TRANSDUCTION OF EPSTEIN-BARR VIRUS-TRANSFORMED B CELLS", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 1, January 2000 (2000-01-01), pages 354 - 362, XP000906911, ISSN: 0022-538X *
WICKHAM T J ET AL: "Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 71, no. 11, 1 November 1997 (1997-11-01), pages 8221 - 8229, XP002078898, ISSN: 0022-538X *
WICKHAM T J: "TARGETING ADENOVIRUS", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 7, no. 2, January 2000 (2000-01-01), pages 110 - 114, XP001055892, ISSN: 0969-7128 *

Also Published As

Publication number Publication date
AU2003273463A8 (en) 2004-02-16
WO2004011489A2 (en) 2004-02-05
AU2003273463A1 (en) 2004-02-16
FR2842823A1 (en) 2004-01-30

Similar Documents

Publication Publication Date Title
ATE403736T1 (en) ONCOLYTIC ADENOVIRAL VECTORS
CA2477954A1 (en) Means and methods for the production of adenovirus vectors
WO2010086189A3 (en) Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
EP2325298A3 (en) Simian adenoviruses SAdV-36, -42.1, -42.2, AND -44 and uses thereof
IS4754A (en) Genes and methods for gene transfer into cells
WO2008084115A3 (en) Lactococcus promoters and uses thereof
WO2010138263A3 (en) Novel aav 's and uses thereof
ATE332965T1 (en) COMPLEMENTARY CELL LINES
WO2005001103A3 (en) Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
WO2006096815A3 (en) NOVEL hTMC PROMOTER AND VECTORS FOR THE TUMOR-SELECTIVE AND HIGH-EFFICIENT EXPRESSION OF CANCER THERAPEUTIC GENES
WO2005118825A3 (en) Chimeric adenoviruses for use in cancer treatment
WO2007070392A3 (en) Adenoviral expression vectors having an expression cassette in the e1 region and an inactivated e2b polymerase
AU5464000A (en) Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins
BR9908018A (en) Modified adenoviruses containing a fiber replacement protein
WO2006119449A3 (en) Modified adenovirus containing a stabilized antibody
WO2006039045A3 (en) Adenoviral vectors able to transduce apcs, potential use in immune response generation
WO2006110240A3 (en) Gene transfer with adenoviruses having modified fiber proteins
JP2009523007A5 (en)
Nettelbeck Virotherapeutics: conditionally replicative adenoviruses for viral oncolysis
WO2003029433A3 (en) Chimeric viral vectors for gene therapy
WO2003008449A8 (en) Ntb-a, a surface molecule involved in natural killer cells activity
WO2004011489A3 (en) Tropism-modified adenoviral vectors, preferably for targeting b-lymphocytes or ovarian cells
WO2001083737A3 (en) Porcine adenovirus type 5 vector and vaccine
WO2004018627A3 (en) Methods for propagating adenovirus and virus produced thereby
PL1760153T3 (en) Adenovirus/alphavirus hybrid vector for the effective administration and expression of therapeutic genes in tumour cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP